TrialAlzheimer's research & therapy2022

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease.

Alan J Lerner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.